The Goldman Sachs Group Has Lowered Expectations for Bruker (NASDAQ:BRKR) Stock Price

Bruker (NASDAQ:BRKR) had its price target decreased by The Goldman Sachs Group from $50.00 to $45.00 in a research report released on Thursday,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the medical research company’s stock.

Other research analysts have also recently issued reports about the stock. Wells Fargo & Company decreased their price objective on shares of Bruker from $75.00 to $60.00 and set an “overweight” rating on the stock in a research report on Thursday, April 17th. Barclays decreased their price target on shares of Bruker from $60.00 to $50.00 and set an “overweight” rating on the stock in a report on Thursday, April 10th. Stifel Nicolaus dropped their price objective on shares of Bruker from $57.00 to $48.00 and set a “hold” rating for the company in a report on Thursday. Citigroup reduced their target price on Bruker from $75.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, April 7th. Finally, Guggenheim reiterated a “buy” rating on shares of Bruker in a report on Monday, February 24th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.10.

Bruker Stock Performance

NASDAQ BRKR opened at $37.79 on Thursday. The company’s 50 day simple moving average is $41.26 and its two-hundred day simple moving average is $51.15. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. Bruker has a 1 year low of $34.10 and a 1 year high of $79.78. The stock has a market capitalization of $5.73 billion, a PE ratio of 49.72, a P/E/G ratio of 2.16 and a beta of 1.23.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Wednesday, May 7th. The medical research company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.01. The company had revenue of $801.40 million for the quarter, compared to the consensus estimate of $763.83 million. Bruker had a return on equity of 21.01% and a net margin of 3.36%. The firm’s revenue was up 11.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.53 earnings per share. Analysts predict that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Monday, March 17th were issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.53%. The ex-dividend date of this dividend was Monday, March 17th. Bruker’s dividend payout ratio is 26.32%.

Institutional Investors Weigh In On Bruker

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BRKR. London Co. of Virginia raised its stake in shares of Bruker by 78.4% during the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company’s stock valued at $245,820,000 after acquiring an additional 1,843,294 shares during the last quarter. Brown Advisory Inc. raised its position in Bruker by 18.9% during the 1st quarter. Brown Advisory Inc. now owns 2,410,137 shares of the medical research company’s stock valued at $100,599,000 after purchasing an additional 383,425 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Bruker by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 2,013,741 shares of the medical research company’s stock worth $118,081,000 after buying an additional 20,273 shares during the period. FIL Ltd grew its position in shares of Bruker by 262.3% in the 4th quarter. FIL Ltd now owns 1,961,416 shares of the medical research company’s stock worth $114,978,000 after buying an additional 1,420,102 shares during the last quarter. Finally, Sculptor Capital LP increased its stake in shares of Bruker by 484.1% during the fourth quarter. Sculptor Capital LP now owns 1,714,015 shares of the medical research company’s stock valued at $100,476,000 after buying an additional 1,420,569 shares during the period. 79.52% of the stock is currently owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.